

Fabian Trillsch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3286279/publications.pdf>

Version: 2024-02-01

95
papers

1,877
citations

257450

24
h-index

302126

39
g-index

100
all docs

100
docs citations

100
times ranked

2996
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes in gynecologic and breast cancer diagnoses during the first wave of the COVID-19 pandemic: analysis from a tertiary academic gynecological center in Germany. Archives of Gynecology and Obstetrics, 2022, 305, 713-718.	1.7	9
2	Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study. Gynecologic Oncology, 2022, 165, 40-48.	1.4	10
3	AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin. Scientific Reports, 2022, 12, 1862.	3.3	5
4	Subcellular Distribution of Thyroid Hormone Receptor Beta in Ovarian Cancer. International Journal of Molecular Sciences, 2022, 23, 2698.	4.1	3
5	A combination of immunohistochemical markers, MUC1, MUC5AC, PAX8 and growth pattern for characterization of mucinous neoplasm of the ovary. International Journal of Gynecological Cancer, 2022, 32, 662-668.	2.5	5
6	Galectin-8 and -9 as prognostic factors for cervical cancer. Archives of Gynecology and Obstetrics, 2022, 306, 1211-1220.	1.7	11
7	The role of resveratrol, Sirtuin1 and RXR α as prognostic markers in ovarian cancer. Archives of Gynecology and Obstetrics, 2022, 305, 1559-1572.	1.7	2
8	A randomized phase II trial of mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FR α)-high recurrent ovarian cancer eligible for platinum-based chemotherapy.. Journal of Clinical Oncology, 2022, 40, TPS5618-TPS5618.	1.6	1
9	NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU. Archives of Gynecology and Obstetrics, 2021, 303, 1331-1345.	1.7	11
10	Nuclear Enolase-1/ MBP-1 expression and its association with the Wnt signaling in epithelial ovarian cancer. Translational Oncology, 2021, 14, 100910.	3.7	4
11	G Protein-Coupled Estrogen Receptor Correlates With Dkk2 Expression and Has Prognostic Impact in Ovarian Cancer Patients. Frontiers in Endocrinology, 2021, 12, 564002.	3.5	11
12	The G-Protein-Coupled Estrogen Receptor (GPER) Regulates Trimethylation of Histone H3 at Lysine 4 and Represses Migration and Proliferation of Ovarian Cancer Cells In Vitro. Cells, 2021, 10, 619.	4.1	13
13	Breast adipose tissue macrophages (BATMs) have a stronger correlation with breast cancer survival than breast tumor stroma macrophages (BTSMs). Breast Cancer Research, 2021, 23, 45.	5.0	7
14	Platelet-Activating Factor Acetylhydrolase Expression in BRCA1 Mutant Ovarian Cancer as a Protective Factor and Potential Negative Regulator of the Wnt Signaling Pathway. Biomedicines, 2021, 9, 706.	3.2	4
15	Functional Analysis of Non-Genetic Resistance to Platinum in Epithelial Ovarian Cancer Reveals a Role for the MBD3-NuRD Complex in Resistance Development. Cancers, 2021, 13, 3801.	3.7	6
16	Identification of a Novel Tumor Microenvironment Prognostic Signature for Advanced-Stage Serous Ovarian Cancer. Cancers, 2021, 13, 3343.	3.7	14
17	Diagnostic workup for endometrioid borderline ovarian tumors (eBOT) requires histopathological evaluation of the uterus. Journal of Ovarian Research, 2021, 14, 89.	3.0	2
18	Changes in Stem Cell Regulation and Epithelial Organisation during Carcinogenesis and Disease Progression in Gynaecological Malignancies. Cancers, 2021, 13, 3349.	3.7	2

#	ARTICLE	IF	CITATIONS
19	The effect of fertility-sparing surgery on sexuality and global quality of life in women with malignant ovarian germ cell and sex cord stromal tumors: an analysis of the CORSETT database of the AGO study group. <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 1541-1549.	1.7	4
20	Endometrial Cancer Lymphadenectomy Trial (ECLAT) (pelvic and para-aortic lymphadenectomy in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 <i>Journal of Gynecological Cancer</i> , 2021, 31, 1075-1079.	2.5	16
21	Trace Amine-Associated Receptor 1 (TAAR1) Is a Positive Prognosticator for Epithelial Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8479.	4.1	7
22	Actin Beta-Like 2 as a New Mediator of Proliferation and Migration in Epithelial Ovarian Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 713026.	2.8	3
23	The Platelet-Activating Factor Receptor's Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by Rupatadine. <i>Cells</i> , 2021, 10, 2337.	4.1	4
24	Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e37.	2.2	5
25	Î2-arrestin 2 Is a Prognostic Factor for Survival of Ovarian Cancer Patients Upregulating Cell Proliferation. <i>Frontiers in Endocrinology</i> , 2020, 11, 554733.	3.5	15
26	Potential of platinum-resensitization by Wnt signaling modulators as treatment approach for epithelial ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2559-2574.	2.5	4
27	Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression Profile. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9169.	4.1	34
28	M2 Macrophages Infiltrating Epithelial Ovarian Cancer Express MDR1: A Feature That May Account for the Poor Prognosis. <i>Cells</i> , 2020, 9, 1224.	4.1	24
29	Cytoplasmic versus nuclear THR alpha expression determines survival of ovarian cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1923-1932.	2.5	8
30	H3K4me3 Is a Potential Mediator for Antiproliferative Effects of Calcitriol (1Î±,25(OH)2D3) in Ovarian Cancer Biology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2151.	4.1	8
31	Cytoplasmic VDR expression as an independent risk factor for ovarian cancer. <i>Histochemistry and Cell Biology</i> , 2020, 154, 421-429.	1.7	9
32	Sirtuin1 expression and survival in endometrial and clear-cell uterine cancer. <i>Histochemistry and Cell Biology</i> , 2020, 154, 189-195.	1.7	6
33	PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 569-577.	2.5	15
34	Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOT-Ov21) study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6068-6068.	1.6	6
35	<p>Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology<p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 7673-7684.	1.9	12
36	EP3 receptor is a prognostic factor in TA-MUC1-negative ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2519-2527.	2.5	8

#	ARTICLE	IF	CITATIONS
37	Correlation of the Aryl Hydrocarbon Receptor with FSHR in Ovarian Cancer Patients. International Journal of Molecular Sciences, 2019, 20, 2862.	4.1	19
38	Interaction of ER α and NRF2 Impacts Survival in Ovarian Cancer Patients. International Journal of Molecular Sciences, 2019, 20, 112.	4.1	25
39	Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer. International Journal of Molecular Sciences, 2019, 20, 295.	4.1	6
40	The Value of Anti-angiogenics in Ovarian Cancer Therapy. , 2019, , 529-543.		0
41	Cyclic transcutaneous bleeding after repeated cesarean section deliveries. American Journal of Obstetrics and Gynecology, 2018, 219, 202.	1.3	0
42	Peri-operative oral immunonutrition in malnourished ovarian cancer patients assessed by the nutritional risk screening. Archives of Gynecology and Obstetrics, 2018, 297, 1533-1538.	1.7	9
43	No need for NMDA receptor antibody screening in neurologically asymptomatic patients with ovarian teratomas. Journal of Neurology, 2018, 265, 431-432.	3.6	2
44	Uterine and Tubal Lavage for Earlier Cancer Detection Using an Innovative Catheter: A Feasibility and Safety Study. International Journal of Gynecological Cancer, 2018, 28, 1692-1698.	2.5	18
45	The genetic landscape of 87 ovarian germ cell tumors. Gynecologic Oncology, 2018, 151, 61-68.	1.4	44
46	Participation of elderly gynecological cancer patients in clinical trials. Archives of Gynecology and Obstetrics, 2018, 298, 797-804.	1.7	9
47	Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).. British Journal of Cancer, 2018, 119, 330-338.	6.4	13
48	Morphology and tumour-infiltrating lymphocytes in high-stage, high-grade serous ovarian carcinoma correlated with long-term survival. Histopathology, 2018, 73, 1002-1012.	2.9	12
49	Prostaglandin receptor EP3 regulates cell proliferation and migration with impact on survival of endometrial cancer patients. Oncotarget, 2018, 9, 982-994.	1.8	12
50	Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium. European Journal of Cancer, 2017, 79, 214-225.	2.8	29
51	A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2017, 23, 7621-7632.	7.0	31
52	Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only. Oncology Letters, 2017, 14, 3302-3308.	1.8	9
53	Inhibition of Wnt signaling as therapeutic option in platinum-resistant ovarian cancer.. Journal of Clinical Oncology, 2017, 35, e17050-e17050.	1.6	3
54	VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients. Oncotarget, 2017, 8, 43218-43227.	1.8	18

#	ARTICLE	IF	CITATIONS
55	Loss of <i>BRCA1</i> promotor hypermethylation in recurrent high-grade ovarian cancer. <i>Oncotarget</i> , 2017, 8, 83063-83074.	1.8	20
56	Lymphonodektomie beim Vulvakarzinom. , 2017, , 167-176.		0
57	Participation of elderly gynecological cancer patients in clinical trials.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21520-e21520.	1.6	0
58	Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. <i>Oncotarget</i> , 2016, 7, 16923-16935.	1.8	207
59	Patterns of distant metastases in vulvar cancer. <i>Gynecologic Oncology</i> , 2016, 142, 427-434.	1.4	47
60	Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in Patients with Epithelial Ovarian Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016, 924, 3-8.	1.6	37
61	The Risk of Contralateral Non-sentinel Metastasis in Patients with Primary Vulvar Cancer and Unilaterally Positive Sentinel Node. <i>Annals of Surgical Oncology</i> , 2016, 23, 2508-2514.	1.5	37
62	Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial. <i>Annals of Oncology</i> , 2016, 27, 1733-1739.	1.2	28
63	E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer. <i>British Journal of Cancer</i> , 2016, 114, 213-220.	6.4	32
64	Sexual activity and function after surgical treatment in patients with (pre)invasive vulvar lesions. <i>Supportive Care in Cancer</i> , 2016, 24, 419-428.	2.2	20
65	Role of IGF-I in Primary Ovarian Cancer - A Study of the OVCAD European Consortium. <i>Anticancer Research</i> , 2016, 36, 1015-22.	1.1	4
66	Sexual Activity and Function in Patients With Gynecological Malignancies After Completed Treatment. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1134-1141.	2.5	25
67	Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer. <i>Frontiers in Oncology</i> , 2015, 5, 211.	2.8	16
68	Systemic treatment of vulvar cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 629-637.	2.4	33
69	Cadherin-11 mRNA and protein expression in ovarian tumors of different malignancy: No evidence of oncogenic or tumor-suppressive function. <i>Molecular and Clinical Oncology</i> , 2015, 3, 1067-1072.	1.0	6
70	Quality of life and sexual function in patients with borderline tumors of the ovary. A substudy of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study group ROBOT study. <i>Supportive Care in Cancer</i> , 2015, 23, 117-123.	2.2	8
71	Surgical staging and prognosis in serous borderline ovarian tumours (BOT): A subanalysis of the AGO ROBOT study. <i>British Journal of Cancer</i> , 2015, 112, 660-666.	6.4	32
72	Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients. <i>British Journal of Cancer</i> , 2015, 113, 1358-1366.	6.4	110

#	ARTICLE	IF	CITATIONS
73	Prognostic impact of chondroitin-4-sulfotransferase CHST11 in ovarian cancer. <i>Tumor Biology</i> , 2015, 36, 9023-9030.	1.8	36
74	The risk of contralateral non sentinel metastasis in patients with primary vulvar cancer and unilaterally positive sentinel node.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16600-e16600.	1.6	1
75	Prognostic and predictive value of primary vs secondary platinum resistance for bevacizumab treatment in platinum-resistant ovarian cancer in the AURELIA trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5552-5552.	1.6	0
76	Podoplanin increases migration and angiogenesis in malignant glioma. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 8663-70.	0.5	19
77	Clinical management of epithelial ovarian cancer during pregnancy. <i>European Journal of Cancer</i> , 2014, 50, 963-971.	2.8	37
78	Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study. <i>Annals of Oncology</i> , 2014, 25, 1320-1327.	1.2	59
79	Surgical staging and its prognostic impact on patients with borderline ovarian tumors (BOT): A subanalysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5562-5562.	1.6	0
80	Surgical management and perioperative morbidity of patients with primary borderline ovarian tumor (BOT). <i>Journal of Ovarian Research</i> , 2013, 6, 48.	3.0	18
81	Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium. <i>Journal of Ovarian Research</i> , 2013, 6, 42.	3.0	41
82	Platelet-Derived Growth Factor Receptor Beta Serum Concentrations during First-Line Therapy in Ovarian Cancer. <i>Oncology</i> , 2013, 85, 69-77.	1.9	5
83	Adjuvant therapy in node-positive vulvar cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 839-844.	2.4	5
84	The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma " Analysis of patient data in the prospective OVCAD study. <i>Gynecologic Oncology</i> , 2013, 131, 15-20.	1.4	99
85	The prognostic significance of Jun transcription factors in ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1673-1680.	2.5	29
86	Value of Tertiary Cytoreductive Surgery in Epithelial Ovarian Cancer: An International Multicenter Evaluation. <i>Annals of Surgical Oncology</i> , 2013, 20, 1348-1354.	1.5	64
87	Secondary Sentinel Node Biopsy After Previous Excision of the Primary Tumor in Squamous Cell Carcinoma of the Vulva. <i>Annals of Surgical Oncology</i> , 2013, 20, 1701-1706.	1.5	30
88	Management of patients with vulvar cancer: a perspective review according to tumour stage. <i>Therapeutic Advances in Medical Oncology</i> , 2013, 5, 183-192.	3.2	43
89	Surgical management and perioperative morbidity of patients with primary borderline ovarian tumor (BOT).. <i>Journal of Clinical Oncology</i> , 2013, 31, e16535-e16535.	1.6	0
90	Lost in effusion. <i>Lancet, The</i> , 2012, 380, 620.	13.7	1

#	ARTICLE	IF	CITATIONS
91	Interval versus primary tumor debulking surgery in advanced ovarian cancer: Analysis of the European OVCAD data.. Journal of Clinical Oncology, 2012, 30, 5071-5071.	1.6	1
92	Clinical management of primary vulvar cancer. European Journal of Cancer, 2011, 47, 2315-2321.	2.8	82
93	Malignant Transformation of a Serous Borderline Tumor and Early Metastasis of Associated Low-Grade Serous Carcinoma Detected on Screening Mammography. Journal of Clinical Oncology, 2011, 29, e763-e765.	1.6	3
94	Clinical management of borderline ovarian tumors. Expert Review of Anticancer Therapy, 2010, 10, 1115-1124.	2.4	65
95	A Pilot Study of Gene Expression-Based Categorization of Pancreas Transplant Biopsies. Transplantation, 2009, 87, 222-226.	1.0	10